Form 4: ANI Pharma SVP Gassert Boosts Stake with Restricted Stock

ANI Pharmaceuticals SVP Chad Gassert acquired 11,116 shares of common stock through a restricted stock award, increasing his direct beneficial ownership.

Summary

• Chad Gassert, SVP Corporate Development & Strategy at ANI Pharmaceuticals Inc. (ANIP), reported changes in his beneficial ownership.
• On February 26, 2026, Gassert acquired 11,116 shares of common stock at a price of $77.15 per share, as a restricted stock award.
• This restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• On February 28, 2026, 2,221 shares were disposed of at $73.9 per share, withheld for tax purposes in connection with the vesting of a previously reported restricted stock grant of 4,342 shares.
• Following these transactions, Gassert directly beneficially owns 74,916 shares of common stock.
• Additionally, Gassert indirectly beneficially owns 158,490 shares of common stock held by Chali Properties LLC, over which he holds voting and dispositive power.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While the transactions are routine compensation, the acquisition of additional shares by a senior executive, even if restricted, generally signals continued confidence in the company's future.

Positives

• The acquisition of 11,116 shares through a restricted stock award indicates continued alignment of management's interests with shareholders, as a portion of compensation is tied to company performance and stock value.

Negatives

• The disposition of 2,221 shares was for tax withholding purposes, which is a standard procedure upon the vesting of restricted stock and not indicative of a negative outlook by the insider.

Future Outlook

The restricted stock award is structured to vest in four equal annual installments, indicating a long-term incentive for the SVP and a commitment to future performance over the next four years.

Industry Context

StockSavvy.ai notes that restricted stock awards are a common form of executive compensation in the pharmaceutical industry, designed to align management incentives with long-term shareholder value creation. Such awards typically reflect confidence in the company's future prospects and serve as a retention mechanism for key executives.

Comparison to Industry Standards

• Restricted stock awards with multi-year vesting schedules are a standard practice across various industries, including pharmaceuticals, to incentivize long-term performance and executive retention. The structure of this award is consistent with typical compensation practices for senior executives in publicly traded companies.

Related Party Transactions

• Chad Gassert indirectly beneficially owns 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power. This represents a related party holding under his control.

Stakeholder Impact

• Shareholders may view the restricted stock award as a positive signal, indicating management's continued commitment and alignment with long-term shareholder interests.
• Employees, particularly other executives, may see this as a standard component of executive compensation, reinforcing the company's incentive structures.

Next Steps

• The restricted stock award will vest in four equal annual installments on February 26, 2027, February 26, 2028, February 26, 2029, and February 26, 2030.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Chad Gassert, Insider Trading, Form 4, Restricted Stock Award, Stock Ownership, Corporate Development, Strategy